O1‐06‐05: Polygenic Scoring for Risk Stratification of Future Cognitive Decline in Mild Cognitive Impairment (MCI) | Zendy

Shoai Maryam | Zendy; Escott-Price Valentina | Zendy; Pither Richard | Zendy; Davis Julie | Zendy; Laws Simon M. | Zendy; Hardy John | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

O1‐06‐05: Polygenic Scoring for Risk Stratification of Future Cognitive Decline in Mild Cognitive Impairment (MCI)

Author(s) -

Shoai Maryam,

Escott-Price Valentina,

Pither Richard,

Davis Julie,

Laws Simon M.,

Hardy John

Publication year - 2016

Publication title -

alzheimer's and dementia

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.713

H-Index - 118

eISSN - 1552-5279

pISSN - 1552-5260

DOI - 10.1016/j.jalz.2016.06.327

Subject(s) - disease , exome sequencing , cohort , snp , medicine , exome , polygenic risk score , set (abstract data type) , cognitive impairment , single nucleotide polymorphism , oncology , bioinformatics , biology , computer science , mutation , genetics , gene , genotype , programming language

tein up-regulated in AD EVs while 39 were down regulated with respect to the CTRL EVs. Up-regulated proteins in AD EVs were related to cell adhesion and motility, extracellular matrix remodeling and stress response, while down-regulated protein were associated with immune response and proteolysis. Overlap analysis with brain tissue proteomic data from pathologicallyconfirmed AD patients showed 8 protein candidates to be selected for validation. Conclusions: Proteomic analysis of CSF EVs may give an opportunity to sample pathologically linked brain-derived proteins in CSF. The establishment of EV isolation methods using clinically available CSF volumes is mandatory to perform biomarker validation. References: 1. Chiasserini D, et al., J Proteomics. 2014;106:191–204.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research